Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Study protocol

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study

Authors: Amelie Deleporte, Marianne Paesmans, Camilo Garcia, Caroline Vandeputte, Marc Lemort, Jean-Luc Engelholm, Frederic Hoerner, Philippe Aftimos, Ahmad Awada, Nicolas Charette, Godelieve Machiels, Martine Piccart, Patrick Flamen, Alain Hendlisz

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Metastatic colorectal cancer (mCRC) may present various behaviours that define different courses of tumor evolution. There is presently no available tool designed to assess tumor aggressiveness, despite the fact that this is considered to have a major impact on patient outcome.

Methods/Design

CORIOLAN is a single-arm prospective interventional non-therapeutic study aiming mainly to assess the natural tumor metabolic progression index (TMPI) measured by serial FDG PET-CT without any intercurrent antitumor therapy as a prognostic factor for overall survival (OS) in patients with mCRC.
Secondary objectives of the study aim to test the TMPI as a prognostic marker for progression-free survival (PFS), to assess the prognostic value of baseline tumor FDG uptake on PFS and OS, to compare TMPI to classical clinico-biological assessment of prognosis, and to test the prognostic value on OS and PFS of MRI-based apparent diffusion coefficient (ADC) and variation of vADC using voxel-based diffusion maps.
Additionally, this study intends to identify genomic and epigenetic factors that correlate with progression of tumors and the OS of patients with mCRC. Consequently, this analysis will provide information about the signaling pathways that determine the natural and therapy-free course of the disease. Finally, it would be of great interest to investigate whether in a population of patients with mCRC, for which at present no known effective therapy is available, tumor aggressiveness is related to elevated levels of circulating tumor cells (CTCs) and to patient outcome.

Discussion

Tumor aggressiveness is one of the major determinants of patient outcome in advanced disease. Despite its importance, supported by findings reported in the literature of extreme outcomes for patients with mCRC treated with chemotherapy, no objective tool allows clinicians to base treatment decisions on this factor. The CORIOLAN study will characterize TMPI using FDG-PET-based metabolic imaging of patients with chemorefractory mCRC during a period of time without treatment. Results will be correlated to other assessment tools like DW-MRI, CTCs and circulating DNA, with the aim to provide usable tools in daily practice and in clinical studies in the future.

Clinical trials.gov number

NCT01591590.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18 (3): 581-592.CrossRefPubMed
2.
Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992, 10 (6): 904-911.
3.
Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003, 361 (9356): 457-464. 10.1016/S0140-6736(03)12461-0.CrossRefPubMed
4.
Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant AM, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ: A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer. 2005, 93 (11): 1236-1243. 10.1038/sj.bjc.6602841.CrossRefPubMedPubMedCentral
5.
Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009, 27 (34): 5727-5733. 10.1200/JCO.2009.23.4344.CrossRefPubMed
6.
Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, Aglietta M, Lonardi S, Corsi D, Turci D, Beretta GD, Fornarini G, Dapretto E, Floriani I, Zaniboni A, Italian Group for the Study of Gastrointestinal Cancer-GISCAD: Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol. 2011, 22 (5): 1236-1242. 10.1093/annonc/mdq580.CrossRefPubMed
7.
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS, MRC COIN Trial Investigators: Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. lancet Oncol. 2011, 12 (7): 642-653. 10.1016/S1470-2045(11)70102-4.CrossRefPubMedPubMedCentral
8.
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012 Oct, 23 (10): 2479-2516. 10.1093/annonc/mds236.CrossRefPubMed
9.
Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M: Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer. 2001, 91 (11): 2033-2038. 10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J.CrossRefPubMed
10.
Tang PA, Bentzen SM, Chen EX, Siu LL: Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007, 25 (29): 4562-4568. 10.1200/JCO.2006.08.1935.CrossRefPubMed
11.
Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ: Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008, 26 (2): 183-189. 10.1200/JCO.2007.13.8099.CrossRefPubMed
12.
Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000, 356 (9227): 373-378. 10.1016/S0140-6736(00)02528-9.CrossRefPubMed
13.
Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. lancet Oncol. 2006, 7 (9): 741-746. 10.1016/S1470-2045(06)70800-2.CrossRefPubMed
14.
Schwarzenbach H, Hoon DS, Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev. 2011, 11 (6): 426-437. 10.1038/nrc3066.CrossRef
15.
Bystrom P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren P, Frodin JE, Glimelius B: Early prediction of response to first-line chemotherapy by sequential [18 F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol. 2009, 20 (6): 1057-1061. 10.1093/annonc/mdn744.CrossRefPubMed
16.
Hendlisz A, Emonts P, Covas A, Ameye L, Paesmans M, Castany Prado Mariadel Rosario R, Machiels G, Van den Eynde M, Vanderlinden B, Flamen P: Is positron emission tomography (PET) with FDG an early predictor of the RECIST morphological response to chemotherapy in metastatic colorectal cancer patients (mCRC)?. J ClinOncol. 2009, 6 (20): 1057-1061.
17.
Higashi K, Clavo AC, Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993, 34 (3): 414-419.PubMed
18.
Nomura K, Miyagawa S, Harada H, Kitamura H, Seki H, Shimada R, Kobayashi A, Noike T, Kawasaki S: Relationship between doubling time of liver metastases from colorectal carcinoma and residual primary cancer. Digestive surgery. 1998, 15 (1): 21-24. 10.1159/000018581.CrossRefPubMed
19.
Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P: Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2012, 23 (7): 1687-1693. 10.1093/annonc/mdr554.CrossRefPubMed
20.
Price P, Jones T: Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer. 1995, 31A (12): 1924-1927.CrossRefPubMed
21.
Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, Landuyt W, Ni Y: Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology. 2005, 237 (2): 492-499. 10.1148/radiol.2372041638.CrossRefPubMed
22.
Hamstra DA, Rehemtulla A, Ross BD: Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007, 25 (26): 4104-4109. 10.1200/JCO.2007.11.9610.CrossRefPubMed
23.
Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies RJ, Stopeck A: Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (New York, NY). 2004, 6 (6): 831-837. 10.1593/neo.03343.CrossRef
24.
Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, Doran S: Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet. 2002, 360 (9329): 307-308. 10.1016/S0140-6736(02)09520-X.CrossRefPubMed
25.
DeVries AF, Kremser C, Hein PA, Griebel J, Krezcy A, Ofner D, Pfeiffer KP, Lukas P, Judmaier W: Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys. 2003, 56 (4): 958-965. 10.1016/S0360-3016(03)00208-6.CrossRefPubMed
26.
Morgan VA, Riches SF, Thomas K, Vanas N, Parker C, Giles S, Desouza NM: Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol. 2011, 84 (997): 31-37. 10.1259/bjr/14556365.CrossRefPubMedPubMedCentral
27.
Hamstra DA, Galban CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL: Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008, 26 (20): 3387-3394. 10.1200/JCO.2007.15.2363.CrossRefPubMedPubMedCentral
28.
Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM: Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011, 102 (1): 95-103. 10.1007/s11060-010-0293-7.CrossRefPubMed
29.
Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005, 102 (45): 16368-16373. 10.1073/pnas.0507904102.CrossRefPubMedPubMedCentral
30.
McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hamalainen E, Stebbings LA, Andersson LC, Flanagan AM, Durbecq V, Ignatiadis M, Kallioniemi O, Heckman CA, Alitalo K, Edgren H, Futreal PA, Stratton MR, Campbell PJ: Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer. 2010, 49 (11): 1062-1069. 10.1002/gcc.20815.CrossRefPubMedPubMedCentral
31.
Dawson SJ, Rosenfeld N, Caldas C: Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013, 369 (1): 93-94.CrossRefPubMed
32.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004, 351 (8): 781-791. 10.1056/NEJMoa040766.CrossRefPubMed
33.
Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006, 12 (14 Pt 1): 4218-4224.CrossRefPubMed
34.
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009, 20 (7): 1223-1229. 10.1093/annonc/mdn786.CrossRefPubMed
35.
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26 (19): 3213-3221. 10.1200/JCO.2007.15.8923.CrossRefPubMed
36.
Matsusaka S, Suenaga M, Mishima Y, Kuniyoshi R, Takagi K, Terui Y, Mizunuma N, Hatake K: Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer science. 2011, 102 (6): 1188-1192. 10.1111/j.1349-7006.2011.01926.x.CrossRefPubMed
37.
Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nature reviews. 2002, 2 (9): 683-693.PubMed
38.
Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010, 37 (1): 181-200. 10.1007/s00259-009-1297-4.CrossRefPubMed
Metadata
Title
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study
Authors
Amelie Deleporte
Marianne Paesmans
Camilo Garcia
Caroline Vandeputte
Marc Lemort
Jean-Luc Engelholm
Frederic Hoerner
Philippe Aftimos
Ahmad Awada
Nicolas Charette
Godelieve Machiels
Martine Piccart
Patrick Flamen
Alain Hendlisz
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-385

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases

Research article

Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer

Research article

Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma

Research article

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST

Technical advance

Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells

Research article

Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits